RxDoctor Payments Data

Daniella Sawma

Family · Williamsville, NYNPI 1295490282

Payments from drug & device makers

$3,796in general payments, 2019–2025

Across 69 payments — averaging $55.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AOP Health US, LLC$2K
  • Pfizer$289
  • Edwards Lifesciences$277
  • Recor Medical Inc$125
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$124
  • Kiniksa Pharmaceuticals International, PLC$122
  • plus $905 from 14 others

What the payments were for

  • Food & beverage$3,796100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,796 in reported general payments places this provider in the 90th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$9,812
Medicare patients
97
Services billed
139

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban88$119,744
JardianceEmpagliflozin42$51,729
EntrestoSacubitril/Valsartan29$36,044
Repatha SureclickEvolocumab28$29,580
BrilintaTicagrelor21$22,381
XareltoRivaroxaban17$15,960
Metoprolol Succinate195$4,691
Atorvastatin Calcium97$1,754
Ezetimibe37$1,363
Rosuvastatin Calcium70$1,285
ClopidogrelClopidogrel Bisulfate44$887
Valsartan27$778
Amlodipine Besylate73$730
Prasugrel Hcl12$586
Flecainide Acetate12$571

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$289$119,74488 claims
Boehringer IngelheimJardiance$85$51,72942 claims
NovartisEntresto$112$36,04429 claims
AstraZenecaBrilinta$96$22,38121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,883 family providers in New York.

Other family in Williamsville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →